Welcome to our dedicated page for KESTRA MED TECHNOLOGIES SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) provides access to the company’s official regulatory documents as a Bermuda-incorporated, Nasdaq-listed wearable medical device and digital healthcare company. These filings offer structured insight into Kestra’s financial condition, governance, and key events related to its Cardiac Recovery System platform and ASSURE Wearable Cardioverter Defibrillator.
Users can review current reports on Form 8-K, where Kestra discloses material information such as quarterly financial results, preliminary performance updates, and significant clinical communications. For example, the company has used Form 8-K to furnish press releases on fiscal quarter results and to report the announcement of ACE-PAS study findings presented at a major cardiology meeting.
Kestra’s proxy materials on Schedule 14A (DEF 14A) describe matters submitted to shareholders, including the election of directors, ratification of the independent registered public accounting firm, and approval of an employee stock purchase plan. These documents also reference the presentation of audited financial statements contained in the company’s Annual Report on Form 10-K.
Over time, investors can also reference annual reports (Form 10-K) and quarterly reports (Form 10-Q), which provide more detailed discussions of Kestra’s business, risk factors, financial statements, and management’s analysis of results. These filings are important for understanding how Kestra reports on commercialization of its wearable defibrillator platform, research and development spending, and broader corporate activities.
On Stock Titan, Kestra’s filings are updated as they are made available through EDGAR. AI-powered summaries help explain the key points of lengthy documents, highlight notable changes from prior periods, and surface items such as financial performance metrics, governance decisions, and major clinical or commercial disclosures. Users can quickly move from high-level summaries to full-text filings for deeper review.
Kestra Medical Technologies, Ltd. furnished an update on its recent performance by announcing that it issued a press release with financial results for the fiscal quarter ended July 31, 2025. The company reported these quarterly results through a press release dated September 11, 2025, which is attached as an exhibit to this report.
The press release is provided for informational purposes and is designated as “furnished” rather than “filed,” meaning it is not automatically incorporated into other securities law filings unless specifically referenced.
Kestra Medical Technologies director Mary Kay Ladone acquired 10,909 restricted stock units (RSUs) on 09/04/2025, each converting into one common share and scheduled to vest on September 4, 2026, subject to continued service. The filing also reports that 12,994 restricted common shares were automatically converted in connection with the issuer's initial public offering from previously held Class A Common Units granted October 7, 2024. Those converted restricted shares vest in three tranches: 4,331 on October 7, 2025; 4,331 on October 7, 2026; and 4,332 on October 7, 2027. The form is signed by the reporting person and identifies her as a director.
Raymond W. Cohen, a director of Kestra Medical Technologies, Ltd. (KMTS), reported two equity transactions. He purchased 17,000 common shares at $17.00 on 03/07/2025 that were reserved under the issuer's IPO reserved share program and were inadvertently omitted from earlier filings. He also received 10,909 restricted stock units (RSUs) on 09/04/2025; each RSU converts into one common share and the RSUs vest on 09/04/2026 subject to continued service. The report shows 29,994 shares beneficially owned after the March purchase and 40,903 shares beneficially owned following the RSU grant.
Conor Hanley, a director of Kestra Medical Technologies, Ltd. (KMTS), reported acquisition of 13,120 restricted stock units (RSUs) on 09/04/2025. The filing states each RSU converts to one common share. Following the reported grant, Hanley beneficially owns 13,120 shares attributable to these RSUs. The award vests in two tranches: 2,212 RSUs vest on 06/04/2026 and 10,908 RSUs vest on 09/04/2026, each contingent on continued service through the vesting date. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
Jeffrey Lawrence Schwartz, a partner at Bain Capital Investors and a director/10% owner of Kestra Medical Technologies, acquired 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts to one common share and the RSUs vest on 09/04/2026 subject to continued service. After the reported acquisition Mr. Schwartz beneficially owns 10,909 shares directly and 27,019,225 shares indirectly, the latter held by Bain Charger Holdings, L.P. and West Affum Holdings, L.P., with Bain Capital entities holding controlling interests. Mr. Schwartz disclaims beneficial ownership except to the extent of his pecuniary interest.
Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), was granted 10,909 restricted stock units (RSUs) on 09/04/2025. Each RSU converts into one common share and the award will vest on 09/04/2026 provided Ms. Kwo remains in service through that date. The Form 4 was filed as an individual filing and signed by an attorney-in-fact, Traci S. Umberger, on 09/08/2025. This disclosure reports a non-derivative equity grant to an insider rather than a market sale or open-market purchase; no option exercise, sale price, or cash consideration is reported.
Elizabeth Kwo, a director of Kestra Medical Technologies, Ltd. (KMTS), reported ownership of 10,909 restricted stock units (RSUs). The RSUs each convert into one common share and are scheduled to vest on 09/04/2026, subject to her continued service. The Form 3 was filed following an event on 09/03/2025 and is the initial statement disclosing her direct beneficial ownership of these non-derivative securities.
Kestra Medical Technologies, Ltd. held its 2025 annual general meeting of shareholders on September 3, 2025. A total of 48,835,102 common shares were voted in person or by proxy, representing approximately 95% of the 51,348,656 shares outstanding and entitled to vote as of July 7, 2025.
Shareholders elected Conor Hanley and Elizabeth Kwo as Class I directors to serve until the 2028 annual meeting and until their successors are duly elected and qualified. The appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending April 30, 2026 was ratified. Shareholders also approved the company’s 2025 Employee Stock Purchase Plan.